Pancreatic cancer is often referred to as the "king of cancers." This label reflects the harsh reality long faced by patients: rapid disease progression, subtle early symptoms, frequent late-stage diagnosis, and limited treatment options. This is especially true for metastatic pancreatic ductal adenocarcinoma (PDAC), where chemotherapy has long been the primary treatment, creating a pressing need for more precise and effective innovative therapies.

In recent years, with continuous breakthroughs in RAS-targeted drug development, the field of PDAC treatment has seen encouraging progress. Recently, the RAS (ON) inhibitor daraxonrasib, developed by Revolution Medicines, achieved positive results in the phase 3 RASolute 302 study. In previously treated patients with metastatic PDAC, daraxonrasib significantly extended overall survival and progression-free survival compared to standard chemotherapy, marking an important advance for this area of high unmet need.

Now, preliminary clinical data released by Tango Therapeutics today opens another door for the future of RAS inhibitors. In patients with metastatic PDAC who have MTAP deletion and carry RAS mutations, the investigational PRMT5 inhibitor vopimetostat, when combined with daraxonrasib, achieved a 92% objective response rate (ORR) and a 100% disease control rate (DCR).

Can a Synthetic Lethal Partner Amplify RAS Inhibitor Potential?

The data from Tango Therapeutics comes from an ongoing phase 1/2 clinical trial. This study evaluates the efficacy and safety of vopimetostat combined with either Revolution Medicines' daraxonrasib or zoldonrasib for treating PDAC or non-small cell lung cancer (NSCLC) patients with MTAP deletion and RAS mutations.

As of the data cut-off date of May 28, 2026, a total of 59 previously treated patients had received vopimetostat-based combination therapy. This included 20 PDAC patients and 5 NSCLC patients in the vopimetostat plus daraxonrasib cohort, and 34 PDAC patients in the vopimetostat plus zoldonrasib cohort. All patients had advanced disease, and over half received the combination as a third-line treatment.

In the dose-escalation cohort for vopimetostat plus daraxonrasib, 12 PDAC patients and 3 NSCLC patients had at least 14 weeks of follow-up and were evaluable for efficacy by the data cut-off date. The data showed an ORR of 92% (11/12, with 9 of the 11 responses confirmed) in PDAC patients, a 6-month progression-free survival (PFS) rate of 90%, and a DCR of 100%. Among the NSCLC patients, all 3 evaluable patients achieved confirmed responses.

It is noteworthy that this combination is not simply putting two drugs together. Vopimetostat is an oral, once-daily, MTA-cooperative PRMT5 inhibitor designed to selectively target cancer cells with MTAP deletion. MTAP deletion alters the metabolic state of cancer cells, making them more dependent on the PRMT5 pathway, thus PRMT5 inhibitors aim to selectively attack these tumor cells through a "synthetic lethal" mechanism. Daraxonrasib, on the other hand, targets the RAS-driven signaling pathway. For tumors with both MTAP deletion and RAS mutations, vopimetostat addresses a metabolic vulnerability while daraxonrasib tackles the core oncogenic signal, giving the combination a clear biological rationale.

The clinical trial data for the vopimetostat and RAS inhibitor combination supports synergistic activity between PRMT5 inhibition and RAS inhibition. For a highly complex cancer with a limited therapeutic window like pancreatic cancer, this strategy combining "targeting the driver + exploiting a synthetic lethal vulnerability" may represent a significant signal of a new phase in precision oncology.

Regarding safety, vopimetostat combined with daraxonrasib was generally well-tolerated across dose levels, with no new safety signals observed. Most adverse events were grade 1 or 2, with the most common treatment-related adverse events including rash, stomatitis/mucositis, and diarrhea. No grade 4 or 5 treatment-related adverse events occurred in the study, nor were there any treatment discontinuations due to adverse events.

Based on these data, Tango plans to rapidly advance vopimetostat plus daraxonrasib into phase 3 development for patients with MTAP-deficient pancreatic cancer. They also plan to initiate a phase 3 randomized controlled trial in the first-line pancreatic cancer setting following feedback from regulatory authorities.

The Era of Combination Therapies for RAS Inhibitors

The breakthrough of RAS inhibitors itself is a significant milestone in the history of oncology drug development. However, looking at industry trends, the next phase of RAS-targeted therapy likely involves not just finding an effective inhibitor, but designing more systematic combination treatment strategies tailored to different tumor types, mutation backgrounds, and resistance mechanisms.

This trend was evident at the recent American Society of Clinical Oncology (ASCO) annual meeting. Beyond the attention on daraxonrasib's pivotal phase 3 data in pancreatic cancer, multiple RAS inhibitor combination regimens are advancing in various cancer types. For instance, in KRAS G12C-mutated NSCLC, the Krascendo-170 study of divarasib combined with pembrolizumab showed positive efficacy, indicating that combining RAS inhibitors with immune checkpoint inhibitors remains a key area of focus.

Simultaneously, other regimens like olomorasib plus pembrolizumab, calderasib (MK-1084) plus pembrolizumab, or calderasib plus cetuximab and chemotherapy reflect developers' efforts to build a richer matrix of combination therapies around RAS inhibitors.

These combinations address several core issues. First, the RAS signaling pathway is a key driver of growth and survival in many tumors, but single-pathway inhibition may face adaptive feedback and resistance. Second, different RAS mutation subtypes, co-mutation backgrounds, and tumor microenvironment variations can influence patient response to monotherapy or combination therapy. Third, to further amplify the clinical value of RAS inhibitors, more refined combination designs with immunotherapies, EGFR pathway inhibitors, chemotherapy, or synthetic lethal strategies are often needed.

The data released by Tango today offers another type of combination approach: not simply finding a partner within the RAS pathway's immediate vicinity, but linking RAS-driven signaling with the metabolic vulnerability of MTAP deletion.

Integrated Platform Empowers RAS Inhibitor and Synthetic Lethal Drug Development

As a global enabler of pharmaceutical innovation, leveraging an integrated, end-to-end CRDMO platform, support is provided for the development of various innovative cancer therapies, including RAS inhibitors and synthetic lethal therapies. For example, the Biology business platform focuses on the highly challenging and closely watched tumor target KRAS G12D, establishing an integrated model system covering resistance mechanism research and translational validation to provide systematic support for innovative drug development.

Based on a deep understanding of KRAS pathway biology and tumor adaptive evolution mechanisms, the platform has successfully developed multiple KRAS G12D inhibitor-induced resistant tumor models, covering typical KRAS-driven tumor types like colorectal, pancreatic, and lung cancers. By combining in vitro induction and in vivo screening strategies, the systematic construction and validation of resistant cell lines and animal models have been achieved.

These models can effectively recapitulate clinically common resistance mechanisms, including key biological processes such as acquired KRAS mutations, RTK feedback activation, MAPK and PI3K–AKT–mTOR signaling reprogramming, cellular phenotypic plasticity, and tumor microenvironment influence, providing reliable tools for evaluating next-generation RAS inhibitors and combination strategies.

Simultaneously, by leveraging an integrated in vivo and in vitro efficacy evaluation system and a biomarker assessment platform, closed-loop validation from mechanism research to efficacy evaluation is achieved, supporting the evaluation of differential activity and mechanism of action of candidate drugs in resistant backgrounds.

Relying on standardized, scalable model development capabilities, the platform can help partners identify potential resistance risks earlier, accelerating the optimization and clinical translation process of KRAS G12D-targeted therapies.

To address challenges in the early development of synthetic lethal drugs, such as target validation, mechanism assessment, and model selection, the platform offers partners comprehensive biology services and solutions, supporting various standalone or integrated projects from target discovery to candidate screening and into the clinic.

For two promising emerging synthetic lethal pathways, PRMT5 and WRN, the platform has developed approximately 50 animal models covering over ten cancer types, including bladder, breast, and gastric cancers, leukemia, and melanoma, providing robust support for the research and evaluation of a new generation of synthetic lethal therapies.

The convergence of RAS inhibitors and synthetic lethal therapies is opening new possibilities for pancreatic cancer treatment. From the positive phase 3 results of daraxonrasib in metastatic PDAC to the early clinical signals of vopimetostat combined with daraxonrasib in PDAC patients with MTAP deletion and RAS mutations, more promising directions are emerging in pancreatic cancer therapy.

For patients and their families, these advances may represent just one step on a long R&D journey. Yet, it is precisely these accumulated scientific breakthroughs that are creating opportunities for more innovative therapies to enter clinical validation and ultimately benefit patients with urgent treatment needs.